Phio Pharmaceuticals (NASDAQ:PHIO) Shares Down 2.5% – Time to Sell?

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) shares traded down 2.5% during mid-day trading on Friday . The stock traded as low as $3.08 and last traded at $3.08. 36,372 shares were traded during trading, an increase of 1% from the average session volume of 36,010 shares. The stock had previously closed at $3.16.

Phio Pharmaceuticals Stock Performance

The stock’s fifty day moving average is $3.05 and its two-hundred day moving average is $5.13. The firm has a market cap of $2.65 million, a price-to-earnings ratio of -0.11 and a beta of 1.43.

Phio Pharmaceuticals (NASDAQ:PHIO) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($3.62) EPS for the quarter, beating the consensus estimate of ($4.59) by $0.97.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells.